Larimar Therapeutics, Inc.

NASDAQ (USD): Larimar Therapeutics, Inc. (LRMR)

Last Price

4.32

Today's Change

-0.51 (10.55%)

Day's Change

4.13 - 4.77

Trading Volume

2,371,626

Profile
LRMR

Exchange:  NASDAQ Global Market NASDAQ Global Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Carole S. Ben-Maimon M.D. Dr. Carole S. Ben-Maimon M.D.

Full Time Employees:  42 42

IPO Date:  2014-06-19 2014-06-19

CIK:  0001374690 0001374690

ISIN:  US5171251003 US5171251003

CUSIP:  517125100 517125100

Beta:  0.71 0.71

Last Dividend:  0.00 0.00

Dcf Diff:  3.84 3.84

Dcf:  0.48 0.48

Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Address

Three Bala Plaza East,
Bala Cynwyd, PA 19004, US

844 511 9056

http://www.larimartx.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment